{"contentid": 487988, "importid": NaN, "name": "Grifols acquires remaining 56% of the US biopharma GigaGen", "introduction": "Spanish drugmaker Grifols today announced the closing of its agreement with GigaGen to acquire its remaining 56% share capital for $80 million.", "content": "<p>Spanish drugmaker Grifols (GRLS: MC) today announced the closing of its agreement with GigaGen to acquire its remaining 56% share capital for $80 million, with the news sending Grifols&rsquo; share up nearly 2% to 19.79 euros by late afternoon.</p>\n<p>Grifols acquired a <a href=\"https://www.thepharmaletter.com/article/grifols-acquires-minority-stake-in-us-biotech-firm\">44% stake in GigaGen</a> in July 2017 for $35 million through Grifols Innovation and New Technology (GIANT), which channels the group's investments in R+D+i companies and other related projects.</p>\n<p>GigaGen is a US biotechnology company specialized in the early discovery and development of recombinant biotherapeutic medicines. GigaGen&rsquo;s research focuses on discovering new biological treatments based on antibodies derived from millions of immune system cells obtained from donors.</p>\n<p>GigaGen currently spearheads several in-house research projects, including the development of the world&rsquo;s first recombinant immunoglobulin and a portfolio of immuno-oncological therapies.</p>\n<p>V&iacute;ctor Gr&iacute;fols Deu, co-chief executive of Grifols, commented: &ldquo;We are further strengthening our innovation strategy by investing in solid projects, such as Alkahest and now GigaGen, with the aim of helping patients live longer and better lives. Projects like these support our long-term vision and have high potential to bolster our corporate growth and business fundamentals.&rdquo;</p>\n<h2><strong>Brings in diversified pipeline of recombinant polyclonal antibodies</strong></h2>\n<p>GigaGen brings a diversified pipeline of recombinant polyclonal antibodies, including GIGA-2050, a recombinant hyperimmune immunoglobulin for the treatment of COVID-19, which is expected to be evaluated in a Phase I trial in the USA in spring 2021 after the recent approval of its Investigational New Drug (IND) application by the Food and Drug Administration.</p>\n<p>The trial, which will be the first-in-human study evaluating recombinant hyperimmune immunoglobulins, will assess the safety and tolerability of a single dose of GIGA-2050 in up to 18 hospitalized patients with confirmed COVID-19.</p>\n<p>Last August, GigaGen announced the publication of research describing a new class of drugs, recombinant hyperimmunes, including its COVID-19 therapy, GIGA-2050. The Californian company&rsquo;s study explains that GIGA-2050 is like a recombinant convalescent serum, enabling production of millions of doses of drug from a few donors.</p>", "date": "2021-03-09 14:59:00", "meta_title": "Grifols acquires remaining 56% of the US biopharma GigaGen", "meta_keywords": "Grifols, GigaGen, Acquisition, 56%, Polyclonal antibodies, COVID-19, Treament", "meta_description": "Grifols acquires remaining 56% of the US biopharma GigaGen", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-09 14:57:56", "updated": "2021-03-09 15:06:19", "access": NaN, "url": "https://www.thepharmaletter.com/article/grifols-acquires-remaining-56-of-the-us-biopharma-gigagen", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "grifols-big-1.png", "image2id": "grifols-small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology, Infectious diseases", "topic_tag": "Companies, mergers and acquisitions, Coronavirus, Focus On", "geography_tag": "Spain, USA", "company_tag": "GigaGen, Grifols", "drug_tag": "GIGA-2050", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-09 14:59:00"}